Name: Name:Sapacitabine
Brand: Angene
SKU: AG00AMGW
Rating: 90 (10 reviews)

Catalog Number:

AG00AMGW

Chemical Name:

Sapacitabine

CAS Number:

151823-14-2

Molecular Formula:

C26H42N4O5

Molecular Weight:

490.6355

MDL Number:

MFCD00919466

IUPAC Name:

N-[1-[(2R,3S,4S,5R)-3-cyano-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide

InChI:

InChI=1S/C26H42N4O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-23(32)28-22-16-17-30(26(34)29-22)25-20(18-27)24(33)21(19-31)35-25/h16-17,20-21,24-25,31,33H,2-15,19H2,1H3,(H,28,29,32,34)/t20-,21+,24-,25+/m0/s1

InChI Key:

LBGFKUUHOPIEMA-PEARBKPGSA-N

SMILES:

CCCCCCCCCCCCCCCC(=O)Nc1ccn(c(=O)n1)[C@@H]1O[C@@H]([C@H]([C@@H]1C#N)O)CO

UNII:

W335P73C3L

Complexity:

775

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

490.316g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

490.645g/mol

Monoisotopic Mass:

490.316g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

135A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

5.2

Title	Journal
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.	The Lancet. Oncology 20121101
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.	Chinese journal of cancer 20120801
Sapacitabine for cancer.	Expert opinion on investigational drugs 20120401
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.	Expert opinion on investigational drugs 20120401
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.	Seminars in oncology 20111001
Applicability of a 'Pick a Winner' trial design to acute myeloid leukemia.	Blood 20110901
Novel agents for the treatment of acute myeloid leukemia in the older patient.	Journal of the National Comprehensive Cancer Network : JNCCN 20110301
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.	Current medicinal chemistry 20110101
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.	British journal of cancer 20101026
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100110
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.	Current opinion in hematology 20080301
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.	British journal of cancer 20070828
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.	Investigational new drugs 20061101
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.	Investigational new drugs 20060701
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.	Current opinion in investigational drugs (London, England : 2000) 20060601
Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer.	Cancer research 20040301
Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer.	Cancer research 20030901
High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.	Cancer research 20030515